Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Chr. Olesen Synthesis

Chr. Olesen Synthesis
2011 FOUNDED
PRIVATE STATUS
Series A LATEST DEAL TYPE
$11.3M LATEST DEAL AMOUNT
1 INVESTORS
Description

Manufacturer of active pharmaceutical ingredients (APIs) and advanced intermediates designed to produce controlled substances comprising semi-synthetic opioids. The company is focused on controlled substances and molecules like Buprenorphine, Codeine Phosphate, Dexamfetamine, Hydromorphone and Lisdexamfetamine and also offers an election of other APIs like Pramipexole, Risedronate, Terbinafine and Tolfenamic Acid as well as advanced intermediates, enabling pharmaceutical clients to avail advanced intermediates and APIs.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Primary Office
  • Kanalholmen 8-12
  • 2650 Hvidovre
  • Denmark

+45 36 00 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Chr. Olesen Synthesis’s full profile, request a free trial.

Chr. Olesen Synthesis Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 01-Oct-2015 $11.3M 000.00 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Chr. Olesen Synthesis Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 01-Jan-2011 000000000 Distributors (Healthcare)
To view this company’s complete investment and acquisition history, request access »

Chr. Olesen Synthesis Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000 01-Jan-2011 000000000 Completed
  • 2 buyers
To view this company’s complete exits history, request access »

Chr. Olesen Synthesis Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Signet Healthcare Partners Growth/Expansion Minority 000 0000 000000 0

Chr. Olesen Synthesis Executive Team (4)

Name Title Board
Seat
Contact
Info
Thomas Moestrup Chief Executive Officer & Managing Director
Erik Fischer Head, API Development
Lone Nielsen Finance & Administration Manager
Mads Olesen Chairman

Chr. Olesen Synthesis Board Members (2)

Name Representing Role Since Contact
Info
James Gale Signet Healthcare Partners Board Member 000 0000
Mads Olesen Chr. Olesen Synthesis Chairman 000 0000